文献速递神经肿瘤

WHO II级和III级颅内脑膜瘤的立体定向放疗作为原发根治性或术后治疗较复发脑膜瘤的立体定向放疗疾病控制更佳

Stereotactic radiotherapy as primary definitive or postoperative treatment of intracranial meningioma of WHO grade II and III leads to better disease control than stereotactic radiotherapy of recurrent meningioma.
PubMed 文献 · J Neurooncol · 2017-06-30

本研究评估WHO II级和III级脑膜瘤或复发脑膜瘤接受分次立体定向放疗(SRT)后的长期临床结局、预后因素和生活质量。2002年1月至2015年1月,Erlangen大学医院治疗了131例患者共138个脑膜瘤,原发肿瘤患者接受术后SRT或根治性SRT,复发肿瘤均接受手术联合SRT。原发根治性SRT和术后SRT的8年无进展生存率分别为100%和85%,显著优于复发治疗的42%。

要点

  • 原发脑膜瘤根治性SRT的8年无进展生存率为100%,术后SRT为85%,均显著优于复发治疗的42%。
  • WHO II级脑膜瘤全切除后辅助SRT的8年无进展生存率为83%,显著优于复发辅助SRT的46%。
  • 复发治疗中肿瘤位置(颅底或凸面优于大脑镰)是更好无进展生存的有利预后因素。

核心结论

  • 原发脑膜瘤(根治性或术后)SRT的8年无进展生存率显著优于复发脑膜瘤手术联合SRT。
  • WHO II级脑膜瘤全切除后辅助SRT可有效降低复发风险。

研究设计与样本

  • 回顾性研究,2002年1月至2015年1月在Erlangen大学医院治疗131例患者共138个脑膜瘤(64个WHO II级,16个WHO III级,58个无组织学)。
  • 原发肿瘤中53%(n=53)病灶接受术后SRT,47%(n=47)接受根治性SRT(无手术);复发脑膜瘤全部38个(100%)病灶接受手术联合SRT。
  • SRT多采用28、30或25次分割,参考点中位剂量54.0 Gy。

主要发现

  • 原发根治性SRT的8年无进展生存率为100%(p=0.008),术后SRT为85%(p=0.009),均显著优于复发治疗后(手术+SRT)的42%。
  • WHO II级脑膜瘤全切除后辅助SRT的8年无进展生存率为83%(p=0.016),显著优于复发辅助SRT的46%。
  • 原发治疗后31%的患者和复发治疗后38.5%的患者疼痛症状改善。
  • 复发治疗中肿瘤位置(颅底或凸面优于大脑镰)是更好无进展生存的有利预后因素。

临床怎么用

  • 作者认为WHO II级脑膜瘤全切除后术后SRT可有效降低复发风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this study was to evaluate long-term clinical outcome, prognostic factors and quality of life after adjuvant or definitive fractionated stereotactic radiotherapy (SRT) of meningioma WHO grade II and III or at recurrence. 131 patients with 138 meningioma (64 WHO grade II, 16 WHO grade III, 58 without histology) of the skull base, falx and convexity were treated between 01/2002 and 01/2015 at the Erlangen University Hospital by fractionated stereotactic radiotherapy (SRT) as primary treatment (adjuvant or definitive) and at recurrence. 53% (n = 53) lesions of patients with primary tumour received postoperative SRT and 47% (n = 47) as definitive treatment (without surgery). All 38 lesions (100%) of recurrent meningioma underwent surgery followed by SRT. SRT was mostly given in 28, 30 or 25 fractions to a median dose of 54.0 Gy in the reference point. Progression-free-survival at 8 years for patients with meningioma at primary treatment were significantly better with 100% for patients with definitive SRT (p = 0.008) or 85% for patients with adjuvant SRT (p = 0.009) compared to 42% after treatment (surgery + SRT) of recurrence. Progression-free-survival at 8 years for patients with SRT as adjuvant treatment after gross total resection of WHO grade II meningioma were significantly better at 83% (p = 0.016) compared to 46% after adjuvant SRT of recurrence. In 31% of patients after primary treatment and in 38.5% after recurrence treatment an improvement of pain symptoms was achieved. The favourable prognostic factor for better PFS at recurrence treatment was tumor location (skull base or convexity better compared to the falx). Postoperative SRT of WHO grade II meningioma after gross total resection (GTR) can effectively reduce recurrence risk.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Lubgan D, Rutzner S, Lambrecht U, et al. Stereotactic radiotherapy as primary definitive or postoperative treatment of intracranial meningioma of WHO grade II and III leads to better disease control than stereotactic radiotherapy of recurrent meningioma. J Neurooncol. 2017. PMID: 28667597. doi:10.1007/s11060-017-2540-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。